Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yuxin Du
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Zhongshan Hospital
ORCID:
0009-0001-2965-1910
Observed ORCID:
0009-0001-2965-1910
OpenAlex ID:
A5019199251
Catecholamine-induced cardiotoxicity: A critical element in the pathophysiology of stroke-induced heart injury
2021
·
Yuxin Du
, Laurie J. Demillard
, et al.
·
Life Sciences
·
88
A spatially resolved transcriptome landscape during thyroid cancer progression
2025
·
Tian Liao
, Yu Zeng
, et al.
·
Cell Reports Medicine
·
59
Extracellular vesicles in cardiovascular diseases: From pathophysiology to diagnosis and therapy
2023
·
Yuxin Du
, Lin Wu
, et al.
·
Cytokine & Growth Factor Reviews
·
44
Hemithyroidectomy Versus Total Thyroidectomy for Sporadic Medullary Thyroid Cancer: A Chinese Nationwide Large-Scale Cohort Study
2025
·
Xiao Shi
, Cenkai Shen
, et al.
·
Journal of the National Comprehensive Cancer Network
·
27
Sarcoplasmic Reticulum Ca2+ Dysregulation in the Pathophysiology of Inherited Arrhythmia: An Update
2022
·
Yuxin Du
, Laurie J. Demillard
, et al.
·
Biochemical Pharmacology
·
23
Updated Thresholds of Basal Calcitonin Level and Extent of Lymph Node Metastasis in Initially Treated Medullary Thyroid Cancer
2025
·
Yuxin Du
, Cenkai Shen
, et al.
·
JAMA Otolaryngology–Head & Neck Surgery
·
19
Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2023
·
Cenkai Shen
, Xiao Shi
, et al.
·
Clinical Cancer Research
·
11
The therapeutic effect and targets of cellulose polysaccharide on coronary heart disease (CHD) and the construction of a prognostic signature based on network pharmacology
2022
·
Lang Liu
, Yundi Zhang
, et al.
·
Frontiers in Nutrition
·
11
PDF
Revised Perspective on the AJCC Staging System for Medullary Thyroid Cancer: A Study of Two Nationwide Cohorts
2025
·
Cenkai Shen
, Yuxin Du
, et al.
·
Journal of the National Comprehensive Cancer Network
·
10
A protein-based classifier for differentiating follicular thyroid adenoma and carcinoma
2025
·
Yaoting Sun
, He Wang
, et al.
·
EMBO Molecular Medicine
·
7
Proteogenomic characterization delineates clinically relevant subtypes of advanced differentiated thyroid cancer
2026
·
Tingting Zhang
, Wangpeng Cui
, et al.
·
Cell Reports Medicine
·
1
Do Updated Calcitonin Thresholds More Accurately Predict Lymph Node Metastasis in Medullary Thyroid Cancer?—Reply
2025
·
Yuxin Du
, Yu Wang
·
JAMA Otolaryngology–Head & Neck Surgery
·
1
Supplementary Methods 1 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
Data from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
Table S2 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
Figure S1 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
PDF
Figure S1 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
Figure S2 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
Table S2 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
Figure S2 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
PDF
Figure S3 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
PDF
Figure S3 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
Table S1 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
Table S1 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
Data from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
2024
·
Cenkai Shen
, Xiao Shi
, et al.
Show more works
View as search
Works count:
26
Citation count:
301
H-index:
9
I10-index:
9
Year
Topic
Type